AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
AstraZeneca (AZN) and Amgen’s TEZSPIRE met both co-primary endpoints in the Phase III CROSSING trial for eosinophilic esophagitis. Both doses improved tissue remission and swallowing difficulties versus placebo at week 24, with benefits sustained through week 52.
Given every four weeks, the 210mg and 420mg doses achieved tissue remission in 64.8% and 68.9% of patients at week 24 versus 3.5% with placebo. Swallowing symptom scores fell 18.8 and 22.0 points, respectively, versus 14.7 points with placebo. At week 52, tissue remission rates were 67.8% and 63.3% versus 5.4%; total endoscopic remission—no visible disease features—reached 34.4% and 29.5% versus 4.1%.
The most frequent adverse events were upper respiratory infection, headache and diarrhea. Results were presented at United European Gastroenterology Week 2026.
AstraZeneca (AZN) will present overall survival data from four pivotal Phase III cancer trials at ESMO, October 23–27, 2026. More than 100 abstracts will feature its medicines and pipeline, including five pivotal Phase III trials.
CLARITY-Gastric01 showed a statistically significant overall survival benefit for sonesitatug vedotin versus investigator’s choice of therapy in second- or later-line advanced gastric or gastroesophageal junction cancers with CLDN18.2 expression ≥25%. Other Presidential Symposium presentations cover SAFFRON, testing TAGRISSO plus savolitinib after prior treatment in MET-driven, EGFR-mutated lung cancer; DeLLphi-305, testing IMFINZI plus tarlatamab as maintenance treatment in extensive-stage small cell lung cancer; and VOLGA, testing an IMFINZI-based combination in muscle-invasive bladder cancer. The China-based SANOVO trial tests TAGRISSO plus savolitinib in previously untreated lung cancer.
AstraZeneca (AZN) opened a new global research and development center in Kendall Square, Cambridge, Massachusetts, expanding its research presence in the state.
The opening accompanies an investment of more than $1 billion in Massachusetts, part of its broader $50 billion US investment. AstraZeneca expects the Massachusetts investment to expand its workforce in the state by over 50 percent in the coming years. Together with its genomic medicine site at 100 Binney Street, the new center will house nearly 2,000 researchers and scientists. The 570,000-square-foot facility will support work on oncology, cell therapy, chronic disease and rare disease medicines.
Summit Therapeutics (SMMT) closed AstraZeneca’s (AZN) $2.0 billion equity investment to support development of its investigational cancer therapy ivonescimab.
AstraZeneca purchased approximately 108,955 preferred shares, convertible into Summit common shares at a 1:1,000 ratio. The implied common share price of $18.36 represents a premium to the closing trading price on the investment’s announcement day. Summit plans to use the funds to accelerate development across solid tumors, including combinations with sonesitatug vedotin and Datroway, drugs that deliver chemotherapy through antibodies. The FDA accepted Summit’s ivonescimab marketing application for filing in January 2026, with a target decision date of November 14, 2026.
Daiichi Sankyo (4568) and AstraZeneca (AZN) entered a clinical trial collaboration with Summit Therapeutics (SMMT) to evaluate Datroway combined with ivonescimab.
The collaboration covers multiple tumor types, including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer, testing the combination as an initial treatment. Datroway is an antibody-drug conjugate, which links an antibody to a cancer-killing drug, jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Each company will supply its respective compound and contribute to trial costs. AstraZeneca or Daiichi Sankyo will sponsor the planned combination trials. Each company will retain development and commercial rights to its respective medicine. The agreement establishes planned combination studies; it does not report results from them.
Summit Therapeutics (SMMT) announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab combinations. The agreement covers ivonescimab with Datroway (datopotamab deruxtecan), an antibody linked to a cancer drug that targets TROP2. The companies intend to evaluate the combination across multiple solid tumor settings, including breast and lung cancer, starting with a Phase III trial in first-line triple-negative breast cancer.
AstraZeneca or Daiichi Sankyo will sponsor the planned combination trials. Each company will supply its respective therapy and contribute to trial costs, while retaining development and commercial rights to its own medicine. Ivonescimab remains investigational and is not approved in Summit’s licensed territories, including the United States and Europe.
Summit Therapeutics (SMMT) agreed to a $2 billion convertible preferred-share investment from AstraZeneca (AZN) alongside a signed cancer-trial collaboration.
AstraZeneca will buy approximately 108,955 preferred shares, convertible into Summit common stock at a 1:1,000 ratio. The conversion implies $18.36 per common share, a premium to the closing trading price and 10% above the prior week’s five-day volume-weighted average. Closing is expected by the end of the announcement week, subject to customary conditions.
The signed collaboration will test Summit’s investigational ivonescimab with AstraZeneca’s sonesitatug vedotin in gastrointestinal cancers. Both companies will supply their drugs and share study costs. A separate, non-binding memorandum outlines intended trials combining ivonescimab with other AstraZeneca cancer medicines, including antibody-drug conjugates.
AstraZeneca (AZN) received US Priority Review for an IMFINZI and enfortumab vedotin regimen in muscle-invasive bladder cancer.
The FDA accepted a supplemental Biologics License Application for IMFINZI (durvalumab) given around surgery with enfortumab vedotin given before surgery. The application covers patients who are ineligible for or have declined cisplatin-based chemotherapy. AstraZeneca anticipates an FDA decision in the fourth quarter of 2026; Priority Review is not an approval.
In a planned interim analysis of the VOLGA Phase III trial, the regimen showed statistically significant improvements in event-free survival and overall survival against bladder-removal surgery with or without approved treatment after surgery. Safety was consistent with the known profiles of the two medicines, with no new safety signals identified. Results will be presented at a forthcoming medical meeting.
AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion in the EU as adjuvant monotherapy for adults with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted therapy.
The recommendation is based on phase 3 DESTINY-Breast05, where Enhertu reduced the risk of invasive disease recurrence or death (IDFS) by 53% versus T-DM1 (HR=0.47; 95% CI: 0.34-0.66; p<0.0001). Three-year IDFS was 92.4% with Enhertu versus 83.7% with T-DM1. Disease-free survival was also improved, with a 53% risk reduction and three-year DFS of 92.3% vs 83.5%. The safety profile was consistent with prior experience; ILD/pneumonitis occurred in 9.6% of patients (mostly low grade), including 0.2% grade 5 events. The CHMP opinion now goes to the European Commission for final marketing authorization decision.
AstraZeneca (AZN) reported that ENHERTU (fam-trastuzumab deruxtecan-nxki) significantly improved progression-free survival versus pembrolizumab plus platinum-pemetrexed chemotherapy as 1st-line therapy for unresectable, locally advanced or metastatic HER2-mutant non-squamous NSCLC in the Phase III DESTINY-Lung04 trial.
ENHERTU monotherapy reduced the risk of disease progression or death by 37.0% (HR 0.63; 95% CI 0.50-0.79; p<0.0001), with median PFS of 14.3 months versus 8.3 months for pembrolizumab plus chemotherapy (BICR). Objective response rate was 70.0% (159/227) for ENHERTU versus 44.5% (101/227) for the control arm, and median duration of response was 13.4 vs 9.7 months. Median PFS2 was 22.7 vs 17.3 months (HR 0.80; 95% CI 0.62-1.02).
Median overall survival was 29.3 months with ENHERTU and 33.1 months with pembrolizumab plus chemotherapy (HR 1.15; 95% CI 0.88-1.52), with OS data 46.9% mature and not formally tested. Grade ≥3 treatment-related adverse events were similar (34.1% vs 33.6%), but ILD/pneumonitis occurred in 20.8% of ENHERTU-treated patients, including Grade 5 events.